Advertisement

Topics

PubMed Journals Articles About "Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery" RSS

04:43 EDT 16th August 2018 | BioPortfolio

Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery articles that have been published worldwide.

More Information about "Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery" on BioPortfolio

We have published hundreds of Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery news stories on BioPortfolio along with dozens of Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery Clinical Trials and PubMed Articles about Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery Companies in our database. You can also find out about relevant Study To Evaluate The Safety And Efficacy Of Pradaxar For The Prevention Of Venous Thromboembolism In The Mexican Population Undergoing Elective Total Hip Or Knee Replacement Surgery Drugs and Medications on this site too.

Showing "Study Evaluate Safety Efficacy Pradaxar Prevention Venous Thromboembolism" PubMed Articles 1–25 of 73,000+

Prevention of venous thromboembolism in pregnant patients with a history of venous thromboembolic disease: A retrospective cohort study.

Optimal prophylactic strategies in pregnant women with a history of venous thromboembolism (VTE) are unknown.


Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.

 Warfarin and direct oral anticoagulants (DOACs) are used for the initial treatment and secondary prevention of venous thromboembolism (VTE), and have similar efficacy. Patient concerns and preferences are important considerations when selecting an anticoagulant, yet these are not well studied.

Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: A systemic review and meta-analysis.

The standard for treatment and secondary prevention of venous thromboembolism (VTE) has been vitamin K antagonist (VKA), which might be associated with a higher risk of bleeding particularly in Asian patients. Direct oral anticoagulants (DOAC) have been shown to be safer alternatives for VTE. It remains unclear whether this is the case in Asian ethnicity.


Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.

 This article assesses the impact of renal impairment (RI) on the efficacy and safety of anticoagulation in patients with cancer-associated thrombosis from the Comparison of Acute Treatments in Cancer Hemostasis (CATCH) study (NCT01130025).

A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.

Venous thromboembolism is a common complication of cancer, but the risk of developing venous thromboembolism varies greatly among individuals and depends on numerous factors, including type of cancer. We aimed to develop and externally validate a clinical prediction model for cancer-associated venous thromboembolism.

Impact of venorrhaphy and vein ligation in isolated lower-extremity venous injuries on venous thromboembolism and edema.

Following venous injury, venorrhaphy can restore outflow, although it risks thrombosis and venous thromboembolism (VTE). Vein ligation is a faster option, although it potentially risks extremity edema. The purpose of this study was to evaluate the management of venous injury on VTE and extremity edema in patients with isolated lower-extremity venous injuries.

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE]) has an annual incidence rate of 104-183 per 100,000 person-years. After a VTE episode, the two-year recurrence rate is about 17%. Consequently, effective and safe anticoagulation is paramount. Edoxaban is a direct oral anticoagulant (DOAC) approved VTE treatment. Current safety and efficacy data are derived from clinical trials, and information about treatment durations beyond 12 months are not available.

Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study.

In phase III trials, rivaroxaban demonstrated non-inferiority over enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction of major bleeding. However, compared to provoked VTE, the risk-benefit ratio of rivaroxaban may be different for patients with unprovoked VTE.

The initial report on 1-year outcomes of the feasibility study of the VENITI VICI VENOUS STENT in symptomatic iliofemoral venous obstruction.

The objective of this study was to assess the safety and efficacy of a dedicated venous stent (the VICI VENOUS STENT; VENITI, Fremont, Calif) for treatment of symptomatic iliofemoral venous outflow obstruction.

Direct Oral Anticoagulants in End-Stage Renal Disease.

Patients with end-stage renal disease (ESRD) were excluded from pivotal clinical trials with oral anticoagulants. While such patients are at an increased risk of venous and arterial thromboembolism, their risk of bleeding is also elevated. It is thus of little surprise that stroke prevention with vitamin K antagonists (VKAs) in ESRD patients with atrial fibrillation is controversial, with observational evidence ranging from beneficial to harmful. This uncertainty extends to the less studied use of VKAs for ...

Retrievable Inferior vena cava filters in pregnancy: Risk versus benefit?

Venous thromboembolism remains one of the leading causes of maternal mortality in the developed world. Retrievable inferior vena cava (IVC) filters have a role in the prevention of lethal pulmonary emboli when anticoagulation is contraindicated or has failed [1]. It is unclear whether or not the physiological changes in pregnancy influence efficacy and complications of these devices. The decision to place an IVC filter in pregnancy is complex and there is limited information in terms of benefit and risk to ...

Therapeutic approach for patients with venous thromboembolism attended in emergency departments during routine clinical practice: the EDITH study.

To analyze treatment at discharge/follow-up of patients diagnosed with venous thromboembolism (VTE) in the emergency department (ED).

Early Response to Warfarin Initiation and the Risk of Venous Thromboembolism After Total Joint Arthroplasty.

Venous thromboembolism chemoprophylaxis with warfarin is common after total joint arthroplasty. Early response to warfarin initiation has been theorized to engender a transient increase in the risk of venous thromboembolism. We hypothesized that a rapid rise in the international normalized ratio is a risk factor for venous thromboembolism after total joint arthroplasty.

Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban.

Atrial fibrillation, peripheral and coronary artery disease and venous thromboembolism are major risk factors for stroke, disability, and death in the rapidly growing older (≥ 65 years.) population. In the absence of clear guidelines on the appropriate use of the newer non-vitamin K antagonist oral anticoagulants in this population, we specifically review the available literature for rivaroxaban and the impact of age that may affect the pharmacokinetics, pharmacodynamics, efficacy and safety of this antic...

Multicenter Review of Current Practices Associated With Venous Thromboembolism Prophylaxis in Pediatric Patients After Trauma.

Frequency of venous thromboembolism in pediatric trauma patients admitted to PICUs is not insignificant, ranging up to 6%. Risk factors have been identified in this population. However, there is little consensus of actual venous thromboembolism prophylaxis practice. We examined factors associated with venous thromboembolism prophylaxis in PICUs.

High prevalence of factor V Leiden and prothrombin G20101A mutations in Kashmiri patients with venous thromboembolism.

The genetic variants of the factor V (G1691A), prothrombin (G20210A) and MTHFR (C677T) genes have been widely implicated as inherited risk factors for developing venous thrombosis. This study was undertaken to reveal the frequency of these mutations in Kashmiri patients with venous thromboembolism.

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.

Cancer patients with acute venous thromboembolism (VTE) receiving anticoagulant treatment have increased bleeding risk.

A long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.

Brexpiprazole is a serotonin-dopamine activity modulator with efficacy in acute schizophrenia and relapse prevention. The aim of this Phase 3, multicenter study was to assess the long-term safety, tolerability, and efficacy of treatment with brexpiprazole flexible-dose 1-4 mg/day.

Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.

Venous thromboembolism (VTE) presents a continuing clinical burden to healthcare systems and there are patient groups for whom VTE management is challenging. Depending on the patient profile, the optimal duration of anticoagulation for VTE treatment can be unclear. EINSTEIN CHOICE was a Phase III, randomized, double-blind trial that compared the safety and efficacy of two once-daily (od) doses of the direct, oral factor Xa inhibitor rivaroxaban (20 and 10 mg) with acetylsalicylic acid (ASA; 100 mg daily) ...

Venous Thromboembolism Following Total Knee Arthroplasty: Does Race Matter?

Venous thromboembolism (VTE) (deep venous thrombosis and pulmonary embolism) is a known complication following total knee arthroplasty (TKA). Recent literature has identified differences in VTE risk based on race with African Americans having higher risk of VTE. This study evaluated the impact of race on VTE following TKA using a large multicenter database.

Association of Low Hemoglobin with Symptomatic Venous Thromboembolism in Acutely Ill Hospitalized Medical Patients: an APEX Trial Substudy.

Anemia is a common finding and independent predictor for adverse outcomes in hospitalized patients with medical illness. It remains unclear whether anemia is a risk factor for venous thromboembolism and whether the presence of anemia can refine risk assessment for prediction of venous thromboembolism, thereby adding incremental utility to a validated model.

Direct Oral Anticoagulants and the Paradigm Shift in the Management of Venous Thromboembolism.

The advent of direct oral anticoagulants (DOACs) has revolutionized anticoagulation management in both stroke prevention and venous thromboembolism (VTE) treatment/prevention. Clinical trials and secondary real-world data have shown that DOACs have similar efficacy and, in some cases, improved bleeding safety profiles compared with vitamin K antagonists. Together with benefits of patient convenience, this has shifted the risk-benefit ratio toward long-term anticoagulation. However, current VTE risk assessme...

Venous Thromboembolism in Children with Sickle Cell Disease: A Retrospective Cohort Study.

To describe the cumulative incidence of venous thromboembolism (VTE) in children with sickle cell disease (SCD) followed at a single institution and report on the risk factors associated with VTE development.

Rivaroxaban for Thromboprophylaxis among Patients Recently Hospitalized for Acute Infectious Diseases: A Subgroup Analysis of the MAGELLAN Study.

Despite the well-established association between infection and venous thromboembolism (VTE), there are few data specifically assessing the efficacy and safety of the VTE prophylaxis strategies for patients hospitalized for acute infectious diseases.

Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis.

Direct oral anticoagulants (DOACs) are widely used for secondary prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not established in Antiphospholipid Syndrome (APS) patients. There is only one randomized controlled trial published while others are still ongoing. Many non-randomized studies have been published in this field with conflicting opinions.


Advertisement
Quick Search
Advertisement
Advertisement